Snapshot from Jul 25, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / NHS approves EndoSure and Endotest...
Regulatory regulatory approval

NHS approves EndoSure and Endotest for endometriosis

Analysis based on 15 articles · First reported Jul 06, 2026 · Last updated Jul 07, 2026

Sentiment
30
Attention
2
Articles
15
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The approval may boost adoption of non-invasive diagnostic technologies, benefiting developers of EndoSure and Endotest. It could also reduce long-term healthcare costs by enabling earlier treatment and reducing surgical procedures.

Healthcare Medical devices Diagnostics
Event Summary

The United Kingdom — National Institute for Health and Care Research (NICE) has issued draft guidance approving two new tests, EndoSure and Endotest, for use on the NHS in England and Wales to diagnose endometriosis. The tests are intended to reduce the average nine-year diagnostic delay for the condition, which affects one in ten women of reproductive age. Endotest analyzes saliva for microRNA markers, while EndoSure measures gut electrical signals. The approval is for three years, during which further evidence will be collected. A third test, DotEndo, requires more research. The decision has been welcomed by patient groups and clinicians.

Key Actions
100 United Kingdom — National Institute for Health and Care Research approved
30 United Kingdom — National Institute for Health and Care Research required more research DotEndo
Entities Involved
govactor
United Kingdom — National Institute for Health and Care Research
NICE issued draft guidance approving EndoSure and Endotest for NHS use, a key regulatory decision.
Importance 100.0 Sentiment 20.0
oth
EndoSure
One of two approved tests; measures gut electrical signals to detect endometriosis non-invasively.
Importance 100.0 Sentiment 40.0
oth
Endotest
One of two approved tests; analyzes saliva for microRNA markers of endometriosis.
Importance 100.0 Sentiment 40.0
per
Anastasia Chalkidou
As NICE healthtech programme director, she announced the draft guidance and emphasized the tests' potential.
Importance 50.0 Sentiment 20.0
ngo
Endometriosis UK
CEO Emma Cox welcomed the tests, emphasizing the need for GP education.
Importance 40.0 Sentiment 30.0
per
Gail Busby
Consultant gynaecologist who publicly supported the tests, citing benefits for patients and the NHS.
Importance 30.0 Sentiment 20.0
priv
DotEndo
Third test not approved; NICE required more research before consideration.
Importance 30.0 Sentiment -10.0
per
Emma Cox
CEO of Endometriosis UK, welcomed the tests and called for accompanying GP education.
Importance 20.0 Sentiment 20.0
ngo
All-Party Parliamentary Group on Endometriosis
The group conducted a survey highlighting diagnostic delays, supporting the need for new tests.
Importance 20.0 Sentiment 10.0
per
Ami Robertson
Patient who shared her experience of delayed diagnosis and relief after testing.
Importance 10.0 Sentiment 10.0
per
Simran Chavda
Adolescent patient who received a diagnosis via EndoSure and reported improved quality of life.
Importance 10.0 Sentiment 10.0
per
Sharan Uppal
Mother of Simran Chavda, advocated for the test after her daughter's positive experience.
Importance 5.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.